Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Miles

Showing results (431-440 of 501) with videos related to

Pageof 51
Sort By:
British Journal of Haematology|February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyHang Quach, Liam Fernyhough, Ross Henderson, et al.
Annals of Hematology|March 6, 2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapyChan Y Cheah, Michael Dickinson, Michael S Hofman, et al.
AIDS (London, England)|March 17, 2017
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapyTalia M Mota, Thomas A Rasmussen, Ajantha Rhodes, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2005
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in miceJennifer A Westwood, Mark J Smyth, Michele W L Teng, et al.
Blood Advances|October 6, 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphomaConstantine S Tam, Hang Quach, Andrew Nicol, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
The Australasian Journal of Dermatology|December 28, 2020
Mycosis fungoides and Sézary syndrome: Australian clinical practice statementFriyana K Bhabha, Christopher McCormack, Jillian Wells, et al.
AIDS (London, England)|May 18, 2017
Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndromeThomas A Rasmussen, James McMahon, J Judy Chang, et al.
Internal Medicine Journal|May 30, 2026
Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman diseaseDipti Talaulikar, Jun Yen Ng, Adam Bryant, et al.
Leukemia & Lymphoma|April 15, 2014
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature reviewChan Y Cheah, Michael S Hofman, John F Seymour, et al.
Pageof 51

Showing results (431-440 of 501) with videos related to

Sort By:
Pageof 51
British Journal of Haematology|February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyHang Quach, Liam Fernyhough, Ross Henderson, et al.
Annals of Hematology|March 6, 2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapyChan Y Cheah, Michael Dickinson, Michael S Hofman, et al.
AIDS (London, England)|March 17, 2017
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapyTalia M Mota, Thomas A Rasmussen, Ajantha Rhodes, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2005
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in miceJennifer A Westwood, Mark J Smyth, Michele W L Teng, et al.
Blood Advances|October 6, 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphomaConstantine S Tam, Hang Quach, Andrew Nicol, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
The Australasian Journal of Dermatology|December 28, 2020
Mycosis fungoides and Sézary syndrome: Australian clinical practice statementFriyana K Bhabha, Christopher McCormack, Jillian Wells, et al.
AIDS (London, England)|May 18, 2017
Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndromeThomas A Rasmussen, James McMahon, J Judy Chang, et al.
Internal Medicine Journal|May 30, 2026
Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman diseaseDipti Talaulikar, Jun Yen Ng, Adam Bryant, et al.
Leukemia & Lymphoma|April 15, 2014
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature reviewChan Y Cheah, Michael S Hofman, John F Seymour, et al.
Pageof 51